Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Leukemia. 2020 Jan;34(1):293-295. doi: 10.1038/s41375-019-0548-z. Epub 2019 Aug 21.

Yishai Ofran^{1

2}, Shimrit Ringelstein-Harlev^{3

4}, Ilana Slouzkey⁵, Tsila Zuckerman^{3

4}, Dana Yehudai-Ofir³, Israel Henig³, Ofrat Beyar-Katz³, Michal Hayun³, Avraham Frisch³

¹ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. y_ofran@rambam.health.gov.il.
² The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. y_ofran@rambam.health.gov.il.
³ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
⁴ The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
⁵ Immunology Laboratory, Rambam Health Care Campus, Haifa, Israel.

No abstract available

Publication types